ストックスクリーナーアプリを入手
9.90
2.91%
0.28
アフターアワーズ：
9.85
-0.05
-0.51%
前日終値:
$9.62
開ける：
$9.61
24時間の取引高:
9.07M
Relative Volume:
0.93
時価総額：
$11.54B
収益：
$14.33B
当期純損益:
$-3.79B
株価収益率:
-3.123
EPS:
-3.17
ネットキャッシュフロー:
$1.84B
1週間 パフォーマンス:
+3.13%
1か月 パフォーマンス:
-6.16%
6か月 パフォーマンス:
+14.06%
1年 パフォーマンス:
-14.73%
1日の値動き範囲:
$9.5549
$9.915
1週間の範囲:
$9.425
$9.915
52週間の値動き範囲:
$6.85
$13.55
Viatris Inc Stock (VTRS) Company Profile
VTRS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
9.90 | 11.22B | 14.33B | -3.79B | 1.84B | -3.17 |
|
ZTS
Zoetis Inc
|
146.32 | 63.40B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.64 | 46.17B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
8.97 | 39.39B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.20 | 22.00B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
419.21 | 19.19B | 2.99B | 1.21B | 1.13B | 25.06 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-06 | 開始されました | Goldman | Neutral |
| 2024-07-19 | 再開されました | Jefferies | Buy |
| 2023-10-23 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2023-06-23 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2023-04-24 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2023-02-17 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | アップグレード | Jefferies | Hold → Buy |
| 2022-11-10 | アップグレード | UBS | Sell → Neutral |
| 2022-11-08 | アップグレード | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | 再開されました | Jefferies | Hold |
| 2022-06-14 | 開始されました | UBS | Sell |
| 2022-05-10 | ダウングレード | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-03-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | 開始されました | Citigroup | Neutral |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
| 2021-03-08 | ダウングレード | Goldman | Buy → Neutral |
| 2021-03-02 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-02-26 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | 開始されました | Argus | Hold |
| 2020-12-14 | 開始されました | Bernstein | Mkt Perform |
すべてを表示
Viatris Inc (VTRS) 最新ニュース
Viatris Inc. (VTRS) Stock Analysis: Exploring a Potential 20% Upside Amid High Dividend Yield - DirectorsTalk Interviews
Will Viatris Inc. stock continue dividend increasesMarket Performance Summary & Risk Controlled Swing Alerts - newser.com
What drives Viatris Inc stock priceBear Market Strategies & Free Unstoppable Trading Performance - earlytimes.in
What drives Viatris Inc VIA stock priceStock Buyback Updates & Build Wealth With Expert Timing Advice - earlytimes.in
What analysts say about Viatris Inc stockTrendline Breakouts & Minimal Investment Trading Plans - Early Times
What analysts say about Viatris Inc VIA stockCandlestick Trading Patterns & Identify Breakout Stocks - earlytimes.in
Viatris Inc VIA Stock Analysis and ForecastFederal Reserve Announcements & Explosive Profit Growth - Early Times
Quantitative breakdown of Viatris Inc. recent moveJuly 2025 Trends & Intraday High Probability Alerts - newser.com
Is Viatris Stock Underperforming the Nasdaq? - MSN
Is Viatris Stock Underperforming The Nasdaq? - Barchart.com
Viatris: Indore Plant Could Boost 2026 Numbers (NASDAQ:VTRS) - Seeking Alpha
Viatris Nixes Biogen's Extra 1-Year Protection Over MS Drug - Law360
Viatris Inc. (VTRS) Gains FDA Approval for First Generic Iron Sucrose Injection - Insider Monkey
How Viatris’ (VTRS) Removal from the FTSE All-World Index Could Affect Investor Sentiment - Sahm
Viatris Inc.(NasdaqGS: VTRS) dropped from FTSE All-World Index - MarketScreener
Viatris (VTRS): Evaluating Valuation Following FDA Nod for Generic Iron Sucrose and Pipeline Progress - Sahm
Street Watch: Is Viatris Inc a defensive stock2025 Technical Patterns & Weekly Stock Performance Updates - خودرو بانک
Fundamentals Check: Is now the right time to enter Viatris IncJuly 2025 Spike Watch & Target Return Focused Picks - khodrobank.com
Trading Recap: Can Viatris Inc. withstand a market correctionInsider Selling & Precise Trade Entry Recommendations - khodrobank.com
Forecast Cut: How do insiders feel about Viatris IncWeekly Stock Report & Long Hold Capital Preservation Tips - خودرو بانک
Short Covering: Will Viatris Inc stock hit new highs in YEAROil Prices & Free Verified High Yield Trade Plans - khodrobank.com
VIX Spike: Can Viatris Inc ride the EV waveRisk Management & Reliable Momentum Entry Alerts - خودرو بانک
Viatris Inc. (VTRS) Enters $515M IV Iron Market With FDA Green Light - MSN
Viatris (VTRS) Recovers Slightly But Struggles Amid Market Conce - GuruFocus
Viatris rises after a steep seven-day slide - MSN
Day 7 of Loss Streak for Viatris Stock with -9% Return (vs. -20% YTD) [9/16/2025] - Trefis
Institution Moves: Can Viatris Inc ride the EV waveLong Setup & Daily Momentum Trading Reports - خودرو بانک
Volatility Watch: Is Viatris Inc stock suitable for long term investing2025 Bull vs Bear & Weekly High Conviction Trade Ideas - خودرو بانک
Market Moves: Is now the right time to enter Viatris IncJuly 2025 Price Swings & Low Risk High Reward Trade Ideas - khodrobank.com
Viatris wins FDA nod for generic iron sucrose injection targeting Daiichi’s Venofer - MSN
Aug Swings: Is now the right time to enter Viatris IncJuly 2025 Spike Watch & Target Return Focused Picks - khodrobank.com
Market Leaders: Can Viatris Inc. navigate macro headwindsQuarterly Profit Report & Consistent Return Strategy Ideas - خودرو بانک
Viatris chief commercial officer Le Goff sells $72k in stock - Investing.com Nigeria
Viatris chief commercial officer Le Goff sells $72k in stock By Investing.com - Investing.com South Africa
Acute myocardial infarction Market Analysis: Epidemiology Insights, Therapies, Companies, by DelveInsight | Idorsia Pharmaceuticals, Viatris, Recardio, AstraZeneca, Faraday Pharmaceuticals, CeleCor Th - Barchart.com
Real time scanner hits for Viatris Inc. explainedMarket Trend Review & Low Risk Profit Maximizing Plans - Newser
Viatris Investors Face Skeptical Judges on Biosimilars Unit (1) - Bloomberg Law News
US Cystic Fibrosis Therapeutics Market Forecast and Company Analysis Report 2025-2033 Featuring Vertex, Abbvie, Novartis, Gilead Sciences, Viatris, Pfizer, AstraZeneca, and F. Hoffmann-La Roche - Yahoo Finance
Viatris receives FDA warning letter for 11 drugs made at India plant - MSN
Trend analysis for Viatris Inc. this weekTreasury Yields & Stepwise Trade Signal Guides - Newser
Is Viatris Inc. Starting a New UptrendEarnings Summary Report & Reliable Momentum Entry Alerts - beatles.ru
Viatris Inc. Forms Double Bottom Pattern — Eyes on Breakout2025 Market WrapUp & Fast Moving Market Watchlists - beatles.ru
What makes Viatris Inc. stock attractive to long term investorsQuarterly Trade Report & AI Forecasted Stock Moves - beatles.ru
Is Viatris Inc. reversing from oversold territoryPortfolio Performance Summary & Consistent Growth Equity Picks - Newser
Custom strategy builders for tracking Viatris Inc.July 2025 Summary & Free Long-Term Investment Growth Plans - Newser
Stock Analysis | Viatris OutlookA Technical Bear Market with Mixed Fundamentals - AInvest
Candlestick signals on Viatris Inc. stock todayJuly 2025 Final Week & Free Weekly Chart Analysis and Trade Guides - Newser
How volatile is Viatris Inc. stockJuly 2025 Action & Free High Accuracy Swing Entry Alerts - خودرو بانک
Will a bounce in Viatris Inc. offer an exitJuly 2025 Short Interest & Weekly Top Performers Watchlists - Newser
When is the best time to exit Viatris Inc.Weekly Stock Analysis & Verified Chart Pattern Signals - Newser
Generic Drugs Market is expected to reach US$ 942.69 billion - openPR.com
Viatris Inc (VTRS) 財務データ
収益
当期純利益
現金流量
EPS
0.07%
4.06%
大文字化:
|
ボリューム (24 時間):